SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues

This second International Alliance for Biological Standardization COVID-19 webinar brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable participation from low- and middle-income countries, to discuss the use of contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Baay, Marc, Neels, Pieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Press 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428779/
https://www.ncbi.nlm.nih.gov/pubmed/32829985
http://dx.doi.org/10.1016/j.biologicals.2020.08.006
_version_ 1783571152607641600
author Baay, Marc
Neels, Pieter
author_facet Baay, Marc
Neels, Pieter
author_sort Baay, Marc
collection PubMed
description This second International Alliance for Biological Standardization COVID-19 webinar brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable participation from low- and middle-income countries, to discuss the use of controlled human infection models to accelerate development and market authorization assessment of a vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
format Online
Article
Text
id pubmed-7428779
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Academic Press
record_format MEDLINE/PubMed
spelling pubmed-74287792020-08-17 SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues Baay, Marc Neels, Pieter Biologicals Article This second International Alliance for Biological Standardization COVID-19 webinar brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable participation from low- and middle-income countries, to discuss the use of controlled human infection models to accelerate development and market authorization assessment of a vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Academic Press 2020-09 /pmc/articles/PMC7428779/ /pubmed/32829985 http://dx.doi.org/10.1016/j.biologicals.2020.08.006 Text en © 2020 The Authors. Published by Elsevier Ltd on behalf of International Alliance for Biological Standardization. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Baay, Marc
Neels, Pieter
SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues
title SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues
title_full SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues
title_fullStr SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues
title_full_unstemmed SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues
title_short SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues
title_sort sars-cov-2 controlled human infection models: ethics, challenge agent production and regulatory issues
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428779/
https://www.ncbi.nlm.nih.gov/pubmed/32829985
http://dx.doi.org/10.1016/j.biologicals.2020.08.006
work_keys_str_mv AT baaymarc sarscov2controlledhumaninfectionmodelsethicschallengeagentproductionandregulatoryissues
AT neelspieter sarscov2controlledhumaninfectionmodelsethicschallengeagentproductionandregulatoryissues

Ejemplares similares